Literature DB >> 30415509

Variability of blood eosinophils in patients in a clinic for severe asthma.

Ewa Rakowski1, Sibo Zhao2, Mengling Liu2,3, Shilpi Ahuja1, Nedim Durmus1, Gabriele Grunig1,3, Maria Curotto de Lafaille1, Yinxiang Wu2, Joan Reibman1,3.   

Abstract

BACKGROUND: Blood eosinophils are used to determine eligibility for agents targeting IL-5 in patients with uncontrolled asthma. However, little is known about the variability of blood eosinophil measures in these patients before treatment initiation.
OBJECTIVE: To characterize variability and patterns of variability of blood eosinophil levels in a real-world clinic for severe asthmatics.
METHODS: Retrospective review of blood eosinophils measured over a 5-year period in patients enrolled in an urban clinic. Repeated measures of blood eosinophil levels in individuals were evaluated, and cluster analysis was performed to characterize patients by eosinophil patterns. Clinical characteristics associated with eosinophil levels and patterns of variability were analysed.
RESULTS: Patients treated in the Bellevue Hospital Asthma Clinic within a 3-month period were identified (n = 219). Blood eosinophil measures were obtained over the previous 5 years. Only 6% (n = 13) of patients had levels that were consistently above 300 cells/μL. Nearly 50% (n = 104) had eosinophil levels that traversed the threshold of 300 cells/μL. In contrast, 102 (46%) had levels that never reached the threshold of 300 cells/μL. Cluster analyses revealed three clusters with differing patterns of levels and variability. There was a suggestion of decreased clinical control and increased atopy in the cluster with the greatest variability in blood eosinophil measures.
CONCLUSION: In an urban clinic for patients referred for uncontrolled asthma, blood measures of eosinophils were variable and showed differing patterns of variability. These data reinforce the need to perform repeated eosinophil blood measures for appropriate designation for therapeutic intervention.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 30415509     DOI: 10.1111/cea.13310

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  3 in total

1.  Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital.

Authors:  Hongwen Li; Qing Zhang; Jingru Wang; Shengnan Gao; Chunxiao Li; Jianxin Wang; Shuhua Zhang; Jiangtao Lin
Journal:  World Allergy Organ J       Date:  2021-09-21       Impact factor: 4.084

2.  Characterization of Persistent Uncontrolled Asthma Symptoms in Community Members Exposed to World Trade Center Dust and Fumes.

Authors:  Joan Reibman; Caralee Caplan-Shaw; Yinxiang Wu; Mengling Liu; Milan R Amin; Kenneth I Berger; Maria L Cotrina-Vidal; Angeliki Kazeros; Nedim Durmus; Maria-Elena Fernandez-Beros; Roberta M Goldring; Rebecca Rosen; Yongzhao Shao
Journal:  Int J Environ Res Public Health       Date:  2020-09-11       Impact factor: 3.390

3.  A Comprehensive Analysis of the Stability of Blood Eosinophil Levels.

Authors:  Bradley E Chipps; Nizar Jarjour; William J Calhoun; Ahmar Iqbal; Tmirah Haselkorn; Ming Yang; Jochen Brumm; Jonathan Corren; Cecile T J Holweg; Mona Bafadhel
Journal:  Ann Am Thorac Soc       Date:  2021-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.